ESMO Immuno-Oncology 2025 at a glance

Get ready for ESMO Immuno-Oncology Congress 2025. LucidQuest’s preview helps you prioritize high-value sessions and plan an efficient, insight-driven agenda.

📅 Build your schedule around the topics that interest you. 📥 Download the ESMO-IO 2025_Preview_by_LucidQuest

Dive deeper

Key Topics From ESMO Immuno 2025 Scientific Presentations

Immune Checkpoint Inhibition (ICI) & Combination Therapies

• Expected durable PD-1–chemotherapy benefits with plateaued survival, reinforcing biomarker-driven, multi-target checkpoint combinations across indications.

COSTAR Lung & AdvanTIG-302

• Expected no OS benefit versus docetaxel or pembrolizumab despite higher ORR, challenging post–PD-1 NSCLC survival advancement.

EMPOWER-Lung 3 & Next-Gen PD-1/VEGF Regimens

• Projected cemiplimab + chemotherapy OS 24.0 vs 12.1 months; RC148 and surufatinib–serplulimab broaden options.

Beyond Lung Cancer

• Ivonescimab + chemotherapy in TNBC: ORR 80%, PFS 15.2 months. MDNA11 + pembrolizumab and BH3120 + pembrolizumab diversify checkpoint backbones.

Neoadjuvant & Adjuvant Immunotherapy

• Perioperative strategies trend toward biomarker-guided intensification using B-cell architecture, BRCA status, and myeloid signatures.

Genomic & B-Cell–Driven Sensitivity Signals

• MMRd responses ~60%; BRCA PV pCR 88.6% vs 51.6%; CatBoost AUC 0.759 supports perioperative sensitivity modeling.

ECT204 & Optimised TIL Strategies

• GPC3+ HCC: DCR 92%, shrinkage 62%, OS 16.5 months. NSCLC TILs: ORR 41.7%, 12-month OS 66.7%.

Radiotherapy & Immunotherapy Synergy

• LEAD LDRT + durvalumab + EP in ES-SCLC projects OS 23.6 months and PFS 8.3 months, indicating additive immune activation.

Artificial Intelligence and Machine Learning at ESMO Immuno-Oncology 2025

High-Dimensional Immune Profiling Platforms

• 719 cancers and 1000+ donors, >2000 subsets; signatures expected for checkpoint efficacy, toxicity, and longitudinal monitoring.

CNN-Based TIL Quantification in LUAD (TCGA)

• Automated TIL density links to improved overall survival (HR ≈ 2) and higher TMB, refining risk stratification.

Standardising PD-L1 CPS in GI Malignancies

• Whole-slide analyzer across 207 tumors raises kappa 0.57 → 0.71, strengthening nivolumab OS separation at CPS ≥ 5.

Benchmarking Neoantigen Predictors Using PCV Trials

• Re-analysis of >2,400 vaccine readouts refines filters, emphasizing MHC-II and B-cell epitopes, while exposing model gaps.

📅 Build your schedule around the topics that interest you.

📥 Download the ESMO-IO 2025_Preview_by_LucidQuest

Contact us for end-to-end conference coverage.